urothelial cancer
Showing NaN - NaN of 14
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Urothelial Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Gemcitabine)
Recruiting
- Urothelial Cancer
- Nivolumab
- +4 more
-
Birmingham, Alabama
- +196 more
Jan 17, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Carcinoma, Transitional Cell, Urinary Bladder Tumors, Urologic Tumors Trial in Worldwide (enfortumab vedotin (EV),
Active, not recruiting
- Carcinoma, Transitional Cell
- +6 more
- enfortumab vedotin (EV)
- +4 more
-
Anchorage, Alaska
- +105 more
Dec 19, 2022
Colorectal Cancer, NSCLC, Triple Negative Breast Cancer Trial in Spain, United Kingdom, United States (GEN1029
Terminated
- Colorectal Cancer
- +6 more
- GEN1029 (HexaBody®-DR5/DR5)
-
New Haven, Connecticut
- +5 more
Nov 11, 2022
Urothelial Cancer Trial in Worldwide (MEDI4736 (Durvalumab), Tremelimumab, Cisplatin)
Active, not recruiting
- Urothelial Cancer
- MEDI4736 (Durvalumab)
- +4 more
-
Los Angeles, California
- +221 more
Nov 2, 2022
Urothelial Cancer Trial in Worldwide (Avelumab, Best Supportive Care, Following the planned interim analysis for this study:
Active, not recruiting
- Urothelial Cancer
- Avelumab
- +2 more
-
Aurora, Colorado
- +370 more
Oct 24, 2022
NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in
Active, not recruiting
- Non-small Cell Lung Cancer
- Urothelial Cancer
- Avelumab 800 mg in combination with pemetrexed / carboplatin
- +3 more
-
Tucson, Arizona
- +45 more
Oct 13, 2022
Urothelial Cancer Trial in Spain (Niraparib plus Cabozantinib)
Recruiting
- Urothelial Cancer
- Niraparib plus Cabozantinib
-
Barcelona, Cataluña, Spain
- +10 more
Feb 8, 2022